Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

March 10, 2018

Responsive image

PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ — Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) Injection significantly reduced the risk of major advers…

Category: Precious Metals